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Abstract
The first Swiss human embryonic stem cell (hESC) line, CH-ES1, has shown features of a malignant cell line. It originated from
the only single blastomere that survived cryopreservation of an embryo, and it more closely resembles teratocarcinoma
lines than other hESC lines with respect to its abnormal karyotype and its formation of invasive tumors when injected into
SCID mice. The aim of this study was to characterize the molecular basis of the oncogenicity of CH-ES1 cells, we looked for
abnormal chromosomal copy number (by array Comparative Genomic Hybridization, aCGH) and single nucleotide
polymorphisms (SNPs). To see how unique these changes were, we compared these results to data collected from the
2102Ep teratocarcinoma line and four hESC lines (H1, HS293, HS401 and SIVF-02) which displayed normal G-banding result.
We identified genomic gains and losses in CH-ES1, including gains in areas containing several oncogenes. These features are
similar to those observed in teratocarcinomas, and this explains the high malignancy. The CH-ES1 line was trisomic for
chromosomes 1, 9, 12, 17, 19, 20 and X. Also the karyotypically (based on G-banding) normal hESC lines were also found to
have several genomic changes that involved genes with known roles in cancer. The largest changes were found in the H1
line at passage number 56, when large 5 Mb duplications in chromosomes 1q32.2 and 22q12.2 were detected, but the
losses and gains were seen already at passage 22. These changes found in the other lines highlight the importance of
assessing the acquisition of genetic changes by hESCs before their use in regenerative medicine applications. They also
point to the possibility that the acquisition of genetic changes by ESCs in culture may be used to explore certain aspects of
the mechanisms regulating oncogenesis.
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Introduction
Human embryonic stem cells (hESCs) and human embryonal
carcinoma cells (hECs) are two pluripotent cell types that share
many characteristics [1] Human ECs are the malignant stem cells
of teratocarcinomas, which are malignant tumors that have
embryonal carcinoma components, and some may form terato-
carcinomas when re-transplanted into an animal [2]. Both hECs
and hESCs can differentiate into many cell types, but the
differentiation potential of hECs is limited compared to that of
hESC lines [1,3,4]. Before the clearly malignant line CH-ES1 [5]
was developed, human ESC lines were reported to be benign; they
form teratomas comprising differentiated tissue components of
the three embryonic germ layers after injection into immune-
incompetent mice, but they usually do not form teratocarcinomas.
After culture adaptation, hESC lines can develop malignant
features [6], but their ability to form tumors has not been analyzed
in detail.
Human ESC lines have been most often derived from the inner
cell mass of blastocyst-stage embryos [7] but they have also been
derived from eight-cell stage morula embryos [8]. Klimanskaya et
al. derived hESC lines from single isolated blastomeres at first by
co-culture with other hESCs [9] but they were subsequently able
to do so without such support [10]. These lines had normal
karyotypes, and they formed teratomas when grown as xenografts.
In another study, Van de Velde et al. [11] were able to obtain
pluripotent cell lines from single blastomeres derived from four-cell
stage embryos. These embryos had been established for this
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10263purpose and were of good quality. Nonetheless, the first line was
karyotypically abnormal.
We established an hESC line from the only surviving
blastomere of a four-cell stage embryo. This single cell survived
freezing and thawing [5] and produced a cell line expressing the
typical markers of hECs and hESCs. This line proved to be
chromosomally very abnormal and was highly invasive when
transplanted into SCID mice [5]. Hence, it has characteristics
more similar to hECs than to hESCs.
In the present study, we have characterized the genomic
changes that may explain the enhanced oncogenicity of the CH-
ES1 teratocarcinoma-like hESC line relative to other pluripotent
cell lines. We used both comparative genomic hybridization
(aCGH) and single nucleotide polymorphism (SNP) genotyping to
detect genomic changes in the CH-ES1 line, the 2102Ep
teratocarcinoma line and four benign hESC lines (H1, HS293,
HS401 and SIVF-02) originating from three different laboratories.
In addition to finding extensive genomic abnormalities in the CH-
ES1 line, we also found that the H1, HS293, HS401 and SIVF-02
lines share the general characteristics of hESCs that have been
described by the International Stem Cell Initiative (ISCI) 1 [12].
We observed suggestive culture adaptation and growth advantages
in these lines, as well as gains of known oncogenes and the possible
deletion or loss of putative yet unrecognized tumor suppressor
genes. The SNP arrays also revealed potentially tumorigenic
changes in the karyotypically normal hESC lines.
Results
In the teratocarcinoma line 2102Ep and in the teratocarcino-
ma-like line CH-ES1, the chromosomal complement was highly
aneuploid (Figure 1). CGH analysis of CH-ES1 confirmed a high
level of genomic imbalances in agreement with earlier G-banding
results. We performed a high resolution CGH analysis that
revealed a higher frequency of genomic losses compared to gains
in CH-ES1 (Table 1). The regions of reduced copy number ranged
from 6 to 88 Mb and involved chromosomes 1q, 3p, 4p, 4q, 8p,
11q, 13q, 15q, 16, 17q, and 18p. Duplicated regions (0.4 to
60 Mb) were seen in chromosomes 2q, 5q, 6p, 6q, 7q, 8q, 9q, 13q,
15q, and 18q (Table 2). There were partial trisomies of
chromosomes 1, 9, 12, 19, 20 and X, and a duplication of
17p13.2-qtel (3.674-tel). Only chromosome 14 was normal in the
CGH assay. When compared to the 2102Ep teratocarcinoma
line in the CGH assay, CH-ES1 displayed two common large
aberrations, namely, duplication in 5q34 and a deletion of
13q32.1-q34 (Table 2).
The CGH array showed extensive chromosomal changes in the
teratocarcinoma line 2102Ep and in the malignant hESC line CH-
ES1. There were also several visible changes in the H1 line at
passage number 56, including partial 5 Mb duplications in 1q32.2
and 22q12.2, and these findings were confirmed by the SNP
analysis. CGH analyses of the three other hESC lines did not
identify any gains or deletions (Figure 2). A gene-level analysis
Figure 1. Cartography of genetic aberrations which were found in the CH-ES1 and, 2102Ep cell lines. A) Line CH-ES1, B) Line 2102Ep.
Blue bars show duplicated regions and red ones show deleted regions.
doi:10.1371/journal.pone.0010263.g001
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deleted genes and 1021 duplicated genes, whereas in 2102Ep, 394
genes were deleted and 7665 genes were duplicated. Similarly to
other hESCs, control H1 cells showed about 71 deleted genes and
1471 duplicated genes (Table 1). When normal variations listed in
the Genomic Variation databases [13] were excluded, 21 genes
were deleted, and 323 were duplicated (Figure 2). The common
deleted genes included BCL3, which is known to be mutated in B
cell lymphomas (Table 3).
Further analyses using Affymetrix 6.0 SNP arrays confirmed all
the changes observed by CGH and also identified an additional
1275 copy number variant sites. Of these, about 33% were shorter
than 43 kb; the median resolution was 44 kb for the Agilent CGH
arrays. About 60% of the CNVs were detected in the CH-ES1 and
2102Ep stem cell lines, consistent with their abnormal behavior
(Figure 3).
After assignment of the identified genes to KEGG pathways, we
found that there were no common pathways among the 21 gene
deletions shared by the H1, CH-ES1 and 2102Ep cells. However,
there were five pathways that were altered among the 323
duplicated genes shared between these cell lines, including MAPK
signaling, axon guidance, natural killer cell-mediated cytotoxicity,
tight junction and Fc epsilon RI signaling pathways (Figure 4A).
Almost all of these pathways were altered by gene deletions in CH-
ES1 and gene duplications in 2102Ep (Figure 4B). However, we
did not find any significantly predominant type of mutation in H1
(Figure 4C).
Out of the 1275 CNVs detected by the SNP arrays, 165 were
not previously reported in the database of Genomic Variants,
suggesting that these are unique to the stem cell lines analyzed and
may be pertinent to their specific behavior (Figure 5A). The
median length of these mutations was approximately 28 kb and
the total average genome coverage was 4.2 Mb per cell line.
Further annotation using the ENTREZ gene database [14]
mapped 181 genes to these unique CNVs. Out of these, 85 were
found to be expressed in normal stem cell lines.
We matched this list of genes with the OMIM disease database
[15] and found that 27 were previously implicated in a range of
disorders encompassing different forms of cancer (CYLD, NOD2,
SLC19A1, COL18A1), cardiovascular (ADRA1B, NEBL, NRG1,
ZFPM2, UMOD) and psychiatric disorders (GABA3, DAOA,
NRG1, KMO, CTNNA3, ZDHHC17, PPP2RB2, OPRD1). The
primers for validation are given in Table S1.
We further detected 1269 LOH sites (Figure 5B). We matched
these with the CNVs and further annotated them according to
the Toronto Database of Variation. The number of annotated
copy number neutral LOHs (or uniparental disomies (UPDs)) was
211, with a median length of 235 kb and coverage of 10 Mb per
cell line. In total, 363 genes reported in the ENTREZ database
[14] were located in the UPD regions. Out of these, 128 were
found to be expressed in normal hESCs. Again, annotation to
OMIM [15] revealed that several cancer-related genes were
involved in these LOH regions (MLH1, ZMAT3, ADCY7,
PIK3CA).
Even the smaller abnormalities involved potential oncogenes, as
illustrated in Figure 4. Both openly malignant lines (2102Ep and
CH-ES1) had multiple large deletions and insertions involving
genes participating in the cell cycle, apoptosis, growth regulation
and oncogenesis (Figure 4, Table S2, Table S3). These included,
for example, MYC, BRCA2, p53, and others the numerous
deleted and duplicated genes according to the pathways they
reperesent are listed in detail in (Table S3). The results regarding
genomic structure indicate the high instability of CH-ES1 and
2102Ep cells. Remarkably, several numerical abnormalities were
observed in the HS401, HS293 and SIVF-02 hESC lines, as
illustrated in Figure 5. Two genes were also verified for copy
number variation on DNA level by quantitave real-time PCR,
namely loss of GRB10 in HS293 and loss of MLLT1 in HS401
(Table 4)
Table 1. Genetic aberrations found in the H1, CH-ES1, and
2102Ep cell lines.
Line Number of genes Status
2102 Ep 394 Deleted
7665 Duplicated
CH-ES1 4019 Deleted
1021 Duplicated
H1 71 Deleted
1471 Duplicated
doi:10.1371/journal.pone.0010263.t001
Table 2. Summary of the genomic aberrations detected in
CH-ES1 and 2102Ep cell lines by CGH-Array.
2102 Ep cells CH-ES1 cells
Cytoband Aberration
Size
(Mb) Cytoband Aberration
Size
(Mb)
1p36-p12 gain 124 1q44 loss 3.8
2p25-p16. gain 52 2q11-q21.2 gain 39
3p26-p11 gain 73 3p26-p16.1 loss 60
5q23.1-q35 gain 62 3p14.1-p12.1 loss 17
7p22-q21.13 gain 88 4p16-q31.21 loss 79
8p23-p12 gain 30 4q34.3-q35 loss 9
9p24-p12 gain 51 5q34 gain 13
11q14.3-q23.3 loss 23 6p25 gain 4
12p13-q24.3 gain 132 6p22.3 gain 2
13q12.3-q34 loss 84 6p21.31-p21.2 gain 4
16p13.3-q23.2 gain 72 6q21-q27 gain 60
17q13.2-q25 gain 78 7q33-q36 gain 25
19p11.3-p12 gain 28 8p23-p12 loss 35
20p13-q13.3 gain 62 8q24.12 9q21.31 gain 25
21q22.11 gain 1.4 11q24.3 gain 0.4
Xp22.3-q28 gain 154 13q11q21.31 loss 6
13q21-q32 loss 42
13q32.1-q34 gain 33
15q11q22.32 loss 10
15q22.32-q26 loss 44
16p13-q24 gain 37
17q22q23.2 loss 88
18p11 loss 9
18q11-q12.3 loss 16
18q12.3-q23 gain 20
loss 39
doi:10.1371/journal.pone.0010263.t002
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(such as RAB6A) were also seen in these hESC lines, which
induced only benign tumors in the mouse teratoma assay.
Validation of mRNA expression by quantitative real time
P C Ro fag i v e ng e n ew i t ha ni n c r e a s e dc o p yn u m b e ro ra
deletion, also showed corresponding modification of its mRNA
level (Table 5). Totally 11 genes that were either duplicated or
deleted in the different hESC lines were tested for their mRNA
expression. The increased copy numbers and deletions were
seen in the hESC line, H1, already at earliest available passage
22 as revealed by the validation assay. The only cell line that
showed altered mRNA expression from what was expected was
the highly malignant CH-ES1 with high level of genomic
imbalances.
Figure 2. The number of genes in CH-ES1, 2102Ep and H1 lines in either deleted or duplicated regions. A) deleted regions, B) duplicated
regions.
doi:10.1371/journal.pone.0010263.g002
Table 3. Deleted genes in common between H1, CH-ES1, and 2102Ep cell lines.
Input ID Entrez Gene ID Symbol Name
ALDH16A1 126133 ALDH16A1 aldehyde dehydrogenase 16 family, member A1
APOC1 341 APOC1 apolipoprotein C-I
APOC2 344 APOC2 apolipoprotein C-II
APOC4 346 APOC4 apolipoprotein C-IV
APOE 348 APOE apolipoprotein E
BCAM 4059 BCAM basal cell adhesion molecule (Lutheran blood group)
BCL3 602 BCL3 B-cell CLL/lymphoma 3
CBLC 23624 CBLC Cas-Br-M (murine) ecotropic retroviral transforming sequence c
CCDC155
CLPTM1 1209 CLPTM1 cleft lip and palate associated transmembrane protein 1
FCGRT 2217 FCGRT Fc fragment of IgG, receptor, transporter, alpha
FLT3LG 2323 FLT3LG fms-related tyrosine kinase 3 ligand
PIH1D1
PTH2
PVRL2 5819 PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B)
RCN3 57333 RCN3 reticulocalbin 3, EF-hand calcium binding domain
RPL13A 23521 RPL13A ribosomal protein L13a
RPS11 6205 RPS11 ribosomal protein S11
SLC17A7 57030 SLC17A7 solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7
TOMM40 10452 TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast)
doi:10.1371/journal.pone.0010263.t003
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The hESC line CH-ES1 showed many characteristics typical of
a teratocarcinoma-derived EC cell line. Spontaneous teratocarci-
nomas generally arise from primordial germ cells, typically in the
testis, but also occasionally in the ovary or at non-gonad sites.
Experimental teratocarcinomas may also be derived from
ectopically transplanted embryos [12]. A single blastomere of a
four-cell stage human embryo could therefore also form a
teratocarcinoma. It is likely that the blastomere cell that gave rise
to the CH-ES1 line had an abnormal genetic constitution, which is
very common in human pre-implantation embryos [16,17].
Human EC cells commonly have nearly triploid genomes and
DNA content with gross chromosomal changes and a large
number of variations [3]. It has been suggested that such tumor
cells originate from a tetraploid derivative of primordial germ cells.
These cells subsequently lose and rearrange their chromosomes to
first generate a seminoma and then the more malignant and
pluripotent EC cells, which stabilize at an approximately 3n DNA
content [18,19]. It is thus tempting to speculate that the
blastomere that gave rise to CH-ES1 may have been tetraploid
and that subsequent chromosomal loss resulted in an EC-like
phenotype by a mechanism comparable to that by which EC cells
arise.
Our results emphasize the importance of not only cytogenetic
testing but also more detailed genetic testing of hESC lines by
microarray methods before their clinical application in regener-
ative medicine. A large proportion of early human embryos are
chromosomally abnormal, particularly those with poor morphol-
ogy or developmental delays. The embryos donated for research
are often of poor quality, but reported chromosomal abnormalities
in hESC lines are not common, at least in early passages. For
instance, all 30 hESC lines derived in our laboratory at Karolinska
Institutet display karyotypically normal G-banding patterns [20].
It may be that genetically abnormal embryos do not form hESC
lines as easily as normal ones. It is unlikely that the abnormalities
in CH-ES1 would have been caused by the derivation process itself
or by early culture, because we used identical conditions to those
used to produce the 30 chromosomally normal hESC lines [20.
Instead, derivation from a single blastomere may play a role, since
Geens et al. [11], who succeeded in deriving hESC lines from
embryos that were established for the study of early development,
obtained a cytogenetically abnormal line.
There are several possible explanations for the malignancy of
the CH-ES1 and the teratocarcinoma lines, including partial
triploidy [21]. Many of the trisomies that have been identified in
cancers and culture-adapted cells [4,17,18] were also seen in CH-
ES1 cells, such as trisomy of chromosomes 1, 12, and X and a
duplication of 17p13.2-qtel(3.674-tel). In addition, there were
trisomies of chromosomes 9, 19, 20 and 21. In fact, only
chromosome 14 was normal in the CGH assays of the CH-ES1
line. It is not difficult to understand why this particular cell line is
particularly malignant and invasive. According to the CGH
analysis, the changes observed in H1 (the oldest hESC line, which
Figure 3. The number of aberrations per cell line detected by Affymetrix SNP6.0 arrays.
doi:10.1371/journal.pone.0010263.g003
Oncogenic Potential of hESC
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10263Oncogenic Potential of hESC
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10263was at passage number 56 at the time of analysis) may have been
there from the beginning. However, it is also possible that these
changes arose during culture adaptation. We do not presently have
CGH or SNP array data from earlier passages or from other
laboratories.
Culture adaptation of hESCs and accumulation of chromo-
somal changes during long term culture occur as a result of the
successive increase of selective growth advantages provided by
certain abnormalities in the cells [4,21,22]. Furthermore, smaller
changes than can be seen by G-banding have been described, and
these may offer growth advantages similar to those that occur in
cancer. Impaired imprinting and aberrations in mitochondrial
DNA have been described [23], and impaired X-chromosome
activation occurs during culture adaptation [24]. Culture adapta-
tion has also been described in teratocarcinoma lines [3]. It is
possible that least some of the aberrations in the studied lines are
caused by culture adaptation. The aneuploidic increases in copy
number of genes that may promote tumor formation, including
ARHGAP26, GRB10, DDHD2, FGFR1, CTNNA3, PTPN1 and
MLLT1 in the apparently stable and karyotypically normal lines
HS293 and HS401, are cause for concern. Among the altered
genes, ARHGAP26 and MLLT1 have been associated with
leukemia-specific translocations, DDHD2, FGFR1 and PTPN1
have tumor-promoting potential in breast cancer, and CTNNA3
may promote tumor formation in urothelial cancer. Furthermore,
a copy of the GRB10 gene, which acts as a growth inhibitor, was
lost from HS293, supporting the idea of an acquired growth
advantage. Such losses or gains of these potential growth- or
cancer-promoting genes may increase the likelihood of malignant
transformation with the accumulation of later mutations.
The SNP analysis was made using different passage levels to see
what possible changes the lines displaying normal G-banding
finding contain. In the quantitative PCR analysis of RNA
expression, eleven genes were analysed for elevated or decreased
expression according to the losses and gains in the different cell
lineages. All the findings of the PCR validation were consistent
with the SNP array results, but the malignant CH-ES-1 behaved
differently.
Translocated genes may come under the influence of different
promoters and enhancers disturbing and altering their gene
expression. This is a possible explanation to decreased PTPN13
mRNA expression although the gene was shown to be duplicated,
and an increased mRNA expression of FH although loss of a gene
copy in the teratocarcinoma-like CH-ES1
Long term testing in immune-suppressed animals is neither an
adequate nor a sufficient model to study cancer transformation of
hESC lines. It will be difficult to exclude the possibility that cells
carrying copy number alterations of growth-promoting or tumor
suppressor genes have malignant potential by studying them in
model organisms. In xeno-models, all tumorigenic cells are more
likely to be rejected than in transplantation between individuals of
the same species [4,25]. Immunosuppression of the recipient
makes the problem of possible tumor formation even more serious.
The only way to avoid such risks is to use cells at the earliest
possible passage number to decrease the likelihood of such
changes.
According to the CGH and SNP array results, the profiles were
consistent among all six cell lines studied. However, as expected,
the higher resolution offered by the SNP arrays revealed 1275
additional changes smaller than 43 kb (the threshold of CGH
Figure 4. Pathway analyses of gained and lost genes in the analysed cell lines. A) The number of pathways which were statistically
significantly enriched per line involving deleted (left panel) and duplicated (right panel) genes. B) The number of lost and gained genes per cell linei n
summary pathways. C) The percentage of genes altered per pathway by deletion or duplication. Only pathways with copy number variations are
shown.
doi:10.1371/journal.pone.0010263.g004
Figure 5. The number of CNVs and UPDs per chromosome and cell line as detected by Affymetrix 6.0 arrays. CH-ES1 and 2102Ep are
the only female lines. A) The numer of CNVs, B) The number of UPDs.
doi:10.1371/journal.pone.0010263.g005
Oncogenic Potential of hESC
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10263resolution). In addition, SNP arrays can identify copy number
neutral aberrations showing LOH, such as gene conversions and
uniparental isodisomies. Altogether, we found 211 segments with a
median length of 235 kb and coverage of 10 Mb per genome that
showed LOH, and these have not been previously recorded as
CNVs. In total, these regions contained 363 ENTREZ [14] genes,
of which 128 were found to be expressed in normal hESCs. We
conclude that the increased resolution offered by the SNP arrays is
required for assessing potentially harmful alterations in hESC
lines.
In conclusion, the first teratocarcinoma-like hESC line derived
from a single blastomere showed many features typical of
malignant cells, such as trisomies, duplications, deletions, and
increased copy numbers of oncogenes, explaining its malignancy.
In addition, benign and cytogenetically normal hESC lines also
displayed many potentially tumorigenic genomic alterations,
which may be due to the derivation method or to the prolonged
culture conditions. Hence, at a minimum, SNP-profiling of the
hESC lines before their use in regenerative medicine is important.
Materials and Methods
The lines HS293 and HS401 were previously derived from fresh
poor quality embryos that had been donated for research after
informed consent in the Fertility Unit of the Karolinska University
Hospital, Huddinge, Sweden, as described [26,27]. They were
derived using postnatal human skin fibroblasts as feeder cells and
Knockout Serum Replacement (SR, Invitrogen)-containing medi-
um. The Ethics Board of the Karolinska Institutet approved the
derivation and research use of these lines. At the time of DNA
extraction, HS293 was at passage number 47, and HS401 was at
passage number 25. The lines have been karyotyped several times
after derivation, and they were found repeatedly to be cytogenet-
ically normal. After injection into SCID mice, they formed benign
teratomas containing differentiated tissue components of the three
germ layers.
The line CH-ES1 was derived under the same culture
conditions as the lines produced at Karolinska Institutet using
postnatal skin fibroblasts and SR-containing medium [5]. The
derivation of this line was accomplished under the ethics
permission and license of Swiss authorities. Surprisingly, the first
karyotype performed at passage number three by G-banding
showed many substantial chromosomal aberrations. Moreover,
when CH-ES1 cells were injected into mice, they induced highly
invasive tumors with clearly malignant cell composition [5]. At the
time of DNA extraction, CH-ES1 was at passage number 19.
The clonal subline 2102Ep, an hEC line derived from a
testicular teratocarcinoma, was maintained by one of us (PWA) in
Sheffield as previously described [28]; DNA was extracted from
the clone at passage number 40.
The hESC lines H1 from WiCell Research Institute (Madison,
WI), SIVF02 (non-GMP line, a kind gift of Sydney IVF, Australia),
CH-ES1 [5], HS293 and HS401 were maintained in DMEM/F-
12 medium supplemented with 20% serum replacement, L-
glutamine, non-essential amino acids, and 4 ng/ml human basic
fibroblast growth factor. All hESC lines were cultured on
irradiated human foreskin fibroblasts and passaged mechanically.
The fibroblast feeders were cultured in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (both from Invitrogen). Cells were mitotically
inactivated by irradiation at 35 Gy before seeding on a gelatin-
coated 6-well plate at 3.5610
5 cells/plate. The hESC culture
medium was changed daily.
Prior to DNA extraction for SNP analysis, cells were cultured
for at least four passages under feeder-free culture conditions on
Matrigel Growth Factor Reduced (Becton Dickinson AG, Basel,
Switzerland) coated 6-well plates with feeder-conditioned medium
(CM). Matrigel was diluted 1:30 with DMEM/F12 and 0.5 ml of
the dilution was added to cover each well of a 6-well plate and
allowed to gel for 1 h at 37uC. Plates were immediately used after
the coating procedure. CM was prepared by incubating stem cell
media overnight on irradiated feeder cells plated at the same
density for hESC culture. CM was harvested after 24 h and
supplemented with 20 ng/mL bFGF immediately before use with
hESC cultures. This procedure was repeated for one week before
discarding the feeder cells.
Array CGH
DNA was extracted from cells using the QUIamp DNA extract
kit (Qiagen Germantown, MD) following standard protocols.
The same DNA samples were used for both SNP arrays and
array-CGH.
Array-CGH was performed using the Agilent Human Genome
CGH Microarray Kit 44B (Agilent Technologies, Santa Clara,
California, USA). This platform is a high-resolution 60-mer
oligonucleotide-based microarray that allows genome-wide surveys
and molecular profiling of genomic aberrations with a resolution
of ,75 kb. Labeling and hybridization were performed following
the protocols provided by Agilent. Briefly, 500 ng of purified DNA
from a patient and a control (Promega Corporation, Madison,
Wisconsin, USA) was double-digested with RSAI and AluI for two
hours at 37uC. After twenty minutes at 65uC, each digested sample
Table 4. Primers used in real-time PCR.
Gene Forward primer (59-39) Reverse primer (59-39)
Size
(bp)
GRB10-A AGGTGCTGGGTAGCATGTTC GGCTACAACACCCCACTGAC 130
GRB10-B TGTAGGGCCTCCAGAATTGA TTTCCATTGAGCATCAAAACAG 138
MLLT1-A CGTCCAGGTGAGGTTAGAGC CCAGAAGACCACCTTCTCCA 145
MLLT1-B CTGACAGCGGCAGATGTTTA GAGAAGAAAACGCGATCCTG 107
HEM3 * TGCACGGCAGCTTAACGAT AGGCAAGGCAGTCATCAAGG 202
doi:10.1371/journal.pone.0010263.t004
Table 5. Primers used in real-time quantitative PCR.
Gene Forward primer (59-39) Reverse primer (59-39)
Size
(bp)
MLLT1 CAGCAAGCCTGAGAAGATCC TTGAAGTGGCCAGTCTCCTC 150
PK1A TCCTGGTTTCCTCTGCAAGT CGTTGTGCATCTTCTTCACC 97
GRB10 GAAGCAGTACAACGCCCCTA CTCTGCACAGAGCAACCTCA 94
FGFR1 TCCGTCAATGTTTCAGATGC TTCCATCTTTTCTGGGGATG 144
EHMT1 AGAGGACAGCAGGACTTCCA TTCCGAACTCAGGTCAGACTC 142
RAB6A TTGCTGACAAGAGGCAAGTG CAAAGCTGCTGCTACACGTC 134
MAP3K15 AGGGCGATAATGTTCTGGTG TCTCAGGTGCCATGTACTGC 135
FAM49B CATATTCTCCCACCCAGCAT TGGCAGGATTTGTCATCTTG 107
JAK1 AACTGAAGTGGACCCCACAC CACCTGCTCCCCTGTATTGT 130
FH TCGATTTTTGGGTTCTGGTC CCATGGTCATTGCTTCACAC 122
PTPN13 ACCTCCACCTGGTGTGCTAC ATCTGAGCTGGTGCTTTGCT 133
GAPDH* GCAGCCCTGGTGACCAG GGGAAGGTGAAGGTCGGA 62
doi:10.1371/journal.pone.0010263.t005
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hours using Cy5-dUTP for the patient DNA and Cy3-dUTP for
the control DNA. Labeled products were purified on columns
and prepared according to the Agilent protocol. After probe
denaturation and pre-annealing with 5 ml of Cot-1 DNA,
hybridization was performed at 65uC with rotation for 40 hours.
After two washing steps the arrays were analyzed with the Agilent
scanner and Feature Extraction software (v9.1.3). A graphical
overview was obtained using the CGH analytics software (v3.4.27).
The identification of aberrant chromosomal regions was
performed manually using CGH-Analytics software (v3.4.27)
(Agilent Technologies) according to the UCSC Genome Bioinfor-
matics, (2010) [29] http://genome.ucsc.edu) and the Database of
Genomic Variants 2010) [13] (http://projects.tcag.ca/variation/)
on the Human March 2006 assembly.
Associations between genomic instability and Pathways, Gene
Ontology and manually assembled gene lists were tested with R/
bioconductor [30] and Webgestalt [31]. Losses and gains were
considered separately, and enrichment was assessed with hyper-
geometric tests corrected for multiple testing using False Discovery
Rate (FDR).
SNP Arrays
The genotyping to detect both copy-number variations and loss
of heterozygosity (LOH) without loss of chromosomal material was
performed using the Affymetrix Genome-Wide Human SNP
Array 6.0 (San Diego, CA). Labeling and hybridization were
performed following the protocols provided by the manufacturer.
The CRMA method [32] from the Aroma Affymetrix package
[33] was used to asses total CNV.
As a CNV neutral reference group, we used data from a set of
20 arrays of nonmalignant blood cell DNA samples that had been
previously hybridized in the same laboratory (JK).
To separate signal from noise, we considered only CNVs with
intensities larger than one standard deviation of the raw copy
number signal across all of the stem cell arrays. Moreover, we
required CNVs to be tagged by at least four consecutive probes.
Further testing by qPCR of CNVs close to the cut off confirmed
the adequacy of this choice.
LOH was estimated using genotyping calls from Affymetrix
proprietary software Genotyping Console (birdseed method) and a
Hidden Markov Chain Method (HMCM) as implemented in the
software dChip. LOH and CNVs were compared in order to
determine Uniparental Disomy (UPD [34] or copy number
neutral LOH.
Verification of copy number variation with quantitative
real-time PCR
Two selected variations in the hESC lines, the deletions of the
GRB10 gene in HS293 and the MLLT1 gene in HS401, were
verified by designing PCR amplicons within the deleted segments.
A copy number neutral amplicon, HEM3, was used as a reference
[35].
Two amplicons per gene were designed in the Primer Express
v2.0 program (table 6). qRT-PCR analyses were performed in
20 ml volumes with 1 x Fast SYBR Green PCR Master Mix
(Applied Biosystems), 10 ng genomic DNA and optimized primer
concentrations: for HEM3 600 nmol/L, and for GRB10 and
MLLT1 400 nmol/L. Each amplicon was quantified in triplicate
using the Fast SYBR program (95uC for 20 s, followed by 40
cycles of 95uC for 3 s and 60uC for 30 s) on a 7500 Real-time
PCR machine (Applied Biosystems). Relative copy number
estimates were derived through DD Ct calculations for the
copy number neutral amplicon, the HEM3 control gene. Three
laboratory control DNA samples were used as standards for
analyzing relative copy number.
RNA extraction and quantitative real time polymerase
chain reaction
Total RNA was extracted from the different cell lineages using
the Trizol reagent according to the manufacturer’s instruction
(Invitrogen). By the time of RNA extraction, HS401 was at
passage 35, HS293 at passage 54, H1 was analysed from three
different passage levels 22, 33 and 69, SIVF-02 at passage 45 and
CH-ES 1 at passage 14. cDNA was synthesized from 1 mg of total
RNA with the SuperScript II First-Strand synthesis system (Life
Technologies). Quantitative RT-PCR measurements of individual
cDNAs were performed in a final volume of 10 ml using SYBR
green PCR master mix (Applied Biosystems) to measure duplex
DNA formation with the 7500 Real-time PCR machine (Appplied
Biosystems). Gene-specific primers were designed using the
Primer3 software [35] with standard selection criteria in order to
amplify approximately 90–150 bp long PCR fragments (table 5).
Real-time PCR primers were used at a final concentration of
100 nM. Melting curve analysis and agarose gel electrophoresis
was performed to monitor production of the appropriate PCR
product. Each PCR reaction was performed in triplicates with
negative controls. The results were normalized to endogenous
GAPDH and PSMB mRNA levels.
Bioinformatics
Putative phenotypically neutral CNV and UPD sites were
purged by comparing the detected changes to the polymorphisms
and aberrations from the database of Genomic Variants
November 2008 Assembly (hg18) [13] (http://projects.tcag.ca/
variation/). The remaining sites were annotated with the genes
from the ENTREZ database (http://www.ncbi.nlm.nih.gov/sites/
entrez) and the genes were further annotated to the Human
disease database David, Bioinformatics Resources. NIH (2009)
[36] (http://david.abcc.ncifcrf.gov/) and OMIM. NIH (2009) [15]
(http://www.ncbi.nlm.nih.gov/OMIM).
Expression microarrays
Microarray data on Affymetrix HGU133plus2 chips (San
Diego, CA) that had been hybridized with normal stem cell lines
Table 6. Summary of selected genes showing gains or losses
in the different cell lineages and their corresponding mRNA
expression.
Gene Sample Chr Aberration mRNA expression
#
MLLT1 HS401 19 loss 2-fold decrease
PK1A HS401 8 gain 2-fold increase
GRB10 HS293 7 loss 2-fold decrease
FGFR1 HS203 8 gain 2-fold increase
EHMT1 H1 9 loss 3 - 4-fold decrease*
RAB6A H1 11 gain 1.3-2-fold increase*
MAP3K15 SIVF-02 X loss 4-fold decrease
FAM49B SIVF-02 8 gain 2-fold increase
JAK1 CH-ES1 1 loss 3-fold decrease
FH CH-ES1 1 loss 1.5-fold increase
PTPN13 CH-ES1 4 gain 3-fold decrease
doi:10.1371/journal.pone.0010263.t006
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evaluate gene activity. Presence calls from the Affymetrix MAS5
algorithm where used to establish whether a gene was expressed in
normal stem cell lines. As the hybridization was performed in two
technical replicates and genes could be interrogated by several
probe sets, we designated a gene as expressed when it was present
at least half of the time it was interrogated.
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